Global survey of physicians’ attitudes toward biologic and biosimilar therapies.

Molinari, Anna Lia; Gewanter, Harry L.; Loaiza‐Bonilla, Arturo; Reilly, Michael S; Kennedy, Brian; Charles, David

doi:10.1200/jco.2016.34.15_suppl.e18025

Cited by 3 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,[21][22][23]27,28,32,38,[40][41][42][43] Four studies used convenience sampling 9,39,48,50 , another study used purposive sampling 33 , while the study by Shamimul-haq et al 30 used cluster sampling and nine studies not reported. [42][43][44][45][46][47][49][50][51][52]…”

Section: Methodological Qualitymentioning

confidence: 99%

“…However, limitations were not reported for 22 studies. 11,20–30,42,44–53 One study suffered low response rate 26 while another study 31 was affected by small sample size. Twelve studies employed random sampling.…”

Section: Methodology For the Reviewmentioning

confidence: 99%

“…Seven articles in this review investigated the attitude of doctors towards generic biosimilar drugs. [48][49][50][51][52][53][54] In Canada, Grabowski et al 48 carried out a survey to evaluate attitudes towards biosimilars drugs among rheumatologists. Only 31% of physicians were familiar with biosimilars.…”

Section: Specialists' Attitude Towards Switching From Brand To Generimentioning

confidence: 99%

See 2 more Smart Citations

Physicians’ perceptions towards brand medicine and its effect on prescribing: A narrative review

Murshid

Mohaidin

2017

Journal of Generic Medicines

View full text Add to dashboard Cite

The purpose of this paper is to examine existing literature on physicians' perceptions towards brand medicines, to examine the extent to which brands influence drug prescription and whether pharmaceutical industry influences the prescription of brands, as well as to examine the loyalty of physicians to a brand when prescribing drugs or willingness to switch to generic drugs. Methods: Related articles published in different online databases from 2000 to 2017 were surveyed; 38 scientific articles indexed in Google Scholar, Science Direct, and PubMed were selected for review. Articles focused on physicians' perceptions towards brand drugs and its effect on prescribing were extracted. The experimental design and quantitative and qualitative methods used in the studies were analyzed. The deductions made in each study were examined in tandem with the objective of the review. Findings: The studies showed that physicians from high-income countries are inclined to prescribe generic drugs more than brand, whereas those from low-income countries heavily prescribe the brand drugs. The studies also revealed that brand influences the prescribing behavior of physicians. Five studies reported that marketing endeavors encourage the physicians to prescribe brand medicines, while three studies stated that physicians have a high loyalty toward brand medicines irrespective of country's income. Other studies provided evidence that physicians are disposed to switching from brand to generic medicines under certain conditions. Marked differences in the prescribing generic drugs use by physicians among different age were observed. General physicians and pediatrics were more likely to suggest switching from the brand to generic drugs. The majority of physicians were familiar with biosimilars drugs. Conclusion: Generally, the studies showed that physicians tend to have mixed views regarding prescribing brand medicines. The perceptions of physicians towards the brand drugs were found to differ in relation to the nature of healthcare system and level of development.

show abstract

Section: Methodological Qualitymentioning

confidence: 99%

Section: Methodology For the Reviewmentioning

confidence: 99%

Section: Specialists' Attitude Towards Switching From Brand To Generimentioning

confidence: 99%

See 1 more Smart Citation

Physicians’ perceptions towards brand medicine and its effect on prescribing: A narrative review

Murshid

Mohaidin

2017

Journal of Generic Medicines

View full text Add to dashboard Cite

show abstract

“…Several surveys conducted in recent years have demonstrated suboptimal knowledge of all aspects of biosimi- Feature lars and highlighted the need for evidence-based education across specialties. 30,31 In response, the FDA recently announced that it was launching an educational campaign to further understanding of biosimilars, including naming conventions ( Figure 2). 32,33 Numerous other medical professional societies have produced or are in the process of producing biosimilar guidelines.…”

Section: Featurementioning

confidence: 99%

Emerging biosimilars market presents opportunities and challenges

Lartigue¹

2018

JCSO

View full text Add to dashboard Cite

New Therapies Emerging biosimilars market presents opportunities and challenges T he development of biologic therapies has led to some of the most significant advances in the treatment of cancer, but these drugs are also very expensive. As patents for the biologics begin to expire, the development of biosimilars has the potential to dramatically cut therapy costs thereby making the therapies more readily accessible to patients. Here, we discuss biosimilar development and the challenges that need to be overcome to create a robust market. Biosimilar, not generic Biologic therapies are derived from living organisms and include the targeted monoclonal antibodies (mAbs) and cell-based therapies that have revolutionized the treatment of certain cancer types. Yet, their greater complexity makes them more difficult to manufacture, store, and administer, making them a costly therapeutic option that ultimately drives up health care costs. According to a 2011 drug expenditure analysis, biologic therapies accounted for more than half of the total expenditure on anticancer drugs in the US health care system. 1,2 Generally, when drug patents expire, other companies can develop their own identical generic versions to increase competition in the marketplace and drive down costs. However, the paradigm for generic development cannot be applied to biologic therapies because the way in which they are manufactured makes it impossible to generate an identical copy. Instead, the Biologics Price Competition and Innovation Act, a provision of the Patient Protection and Affordable Care Act, has allowed for submission of an application for "licensure of a biologic product based on its similarity to a licensed biologic product". 3 These "biosimilars" have been positioned as game-changers in oncology, with the potential to reduce costs and improve access to biologic therapies. With the patents on several blockbuster cancer biologics already expired or due to expire by 2020, an increasing number of biosimilars are being developed. 4 Totality of evidence Biosimilars require more rigorous testing than generics, but they don't require the same type of scientific data that the original biologic products, termed "reference products," did. Therefore, they are governed by legislation unique to them and approved by different regulatory pathways. The US Food and Drug Administration (FDA) has established a unique shortened regulatory pathway for their approval, known as the 351(k) pathway. So whereas the pathway for reference products is geared toward demonstrating patient benefit, biosimilars are required instead to show equivalence to the reference product. 5 Biosimilars are produced through reverse engineering the reference product. Then, through a stepwise process, to generate what the FDA calls a "totality of evidence," biosimilar manufacturers must demonstrate structural and functional similarities (through comparative quality studies) and comparable pharmacokinetics and pharmacodynamics (through comparative nonclinical and clinical studies) to t...

show abstract

“…As of 2015, 17% of all retail prescriptions (676 million prescriptions) were written by advanced practice providers, which is a substantial increase from 9% of all retail prescriptions (327 million prescriptions) in 2010 (IMS Institute for Healthcare Informatics, 2016b). However, many health-care providers have limited awareness and minimal experience regarding biosimilars (Cohen et al, 2017;Hemmington et al, 2017;Mayden, Larson, Geiger, & Watson, 2015;Molinari et al, 2016;Pasina, Casadei, & Nobili, 2016;Rak Tkaczuk & Jacobs, 2014). Therefore, as the use of biosimilars becomes more widespread, advanced practice providers should understand the development process for these agents and the role of biosimilars in increasing treatment options for patients.…”

mentioning

confidence: 99%

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology

Tinsley

Grande

Olson

et al. 2018

JADPRO

View full text Add to dashboard Cite

Biosimilars are biologic products that are highly similar, but not identical, to a licensed reference (or "originator") biologic product. These agents have the potential to provide efficiencies and improve access to treatment for patients. Biosimilars are currently available for use in clinical practice, including oncology indications, and several more are in clinical development. Due to several key differences in their fundamental properties, production and manufacturing of biosimilars is more complex compared with that of small-molecule generic drugs. Accordingly, the generic drug approval process is not suitable or transferable to biosimilars, the approval of which involves extensive and thorough comparison with the originator biologic. Advanced practice providers play an important role in evaluating treatment options available to patients, prescribing, patient education, and product monitoring. In order to perform these tasks effectively, advanced practice providers should understand the concepts related to biosimilars in clinical practice, particularly regarding extrapolation to other indications, product labeling, interchangeability between products, and routine pharmacovigilance, among other clinical considerations. However, many health-care providers have limited awareness and minimal experience regarding biosimilars. Thus, the purpose of this review is to provide an overview of biosimilars and discuss the clinical considerations for oncology advanced practice providers concerning these therapies.

show abstract

Global survey of physicians’ attitudes toward biologic and biosimilar therapies.

Cited by 3 publications

References 0 publications

Physicians’ perceptions towards brand medicine and its effect on prescribing: A narrative review

Physicians’ perceptions towards brand medicine and its effect on prescribing: A narrative review

Emerging biosimilars market presents opportunities and challenges

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology

Contact Info

Product

Resources

About